PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424424
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424424
The global pharmaceutical contract sales outsourcing (CSO) market size is expected to reach US$ 15,346.7 Mn by 2030, from US$ 8,599.2 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 8.6% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 8,599.2 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 8.60% | 2030/2031 Value Projection: | US$ 15,346.7 Mn |
The global pharmaceutical contract sales outsourcing (CSO) market has shown promising growth in recent years. Pharmaceutical manufacturers are increasingly outsourcing their sales and marketing operations to specialized CSO providers in order to focus on drug research and development. CSO firms assist drug makers in optimizing sales operations, managing representative visits, and ensuring promotional compliance with regulatory guidelines. They leverage data-driven insights and technological solutions to enhance sales representative effectiveness and expand physician reach. The outsourcing model enables pharmaceutical companies to access specialized expertise and achieve operational efficiencies without incurring high fixed costs. This cost-effective approach has thus gained traction among biopharma firms looking to streamline commercialization activities.
Market Dynamics:
The global pharmaceutical contract sales outsourcing (CSO) market is driven by factors such as the need of biopharma players to optimize sales costs and boost productivity. Growing complexity of drug promotion regulations particularly in the U.S. also prompts pharmaceutical companies to outsource sales operations to specialized CSO providers well-versed with compliance frameworks. Additionally, technological advancements in customer relationship management and data analytics are translating into increased demand for outsourced sales capabilities. However, volatility in drug pricing environments and unfavorable healthcare reforms in certain regions pose challenges to market players. Furthermore, consolidation in the CSO industry landscape impacts client relationships. Emerging opportunities lie in expansion into non-traditional therapeutic areas and offering value-added services around market access.
Increasing requirement for companies to streamline the sales process and achieve higher efficiency will further aid in the demand for sales planning/performance analytics software. For instance, on November 7, 2023, Accenture, a digital technology company, and Salesforce, Inc., a software company, announced the collaboration to build an Artificial intelligence (AI) powered cloud service for life sciences companies. Under the collaborations, Accenture added its own expertise both in the biomedical research industry and in artificial intelligence technologies to the Salesforce Life Sciences Cloud to help fulfill the new software's mission of making medtech, biotech, and pharma companies more efficient.